Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and byl719

erlotinib hydrochloride has been researched along with byl719 in 5 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(byl719)		Trials
(byl719)		Recent Studies (post-2010) (byl719)
4,3537863,03322227218

Protein Interaction Comparison

ProteinTaxonomyerlotinib hydrochloride (IC50)byl719 (IC50)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)0.5983
Phosphatidylinositol 3-kinase regulatory subunit alphaHomo sapiens (human)0.7672
Delta-type opioid receptorMus musculus (house mouse)2.2
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)0.0348
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)1.663
Serine/threonine-protein kinase mTORHomo sapiens (human)2.2305
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)0.1966
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformRattus norvegicus (Norway rat)2.2

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Antonakos, B; Cooke, VG; Danial, NN; Flemming, D; Hurov, KE; Jones, MD; Korn, JM; Ledell, J; Lehár, J; Mishina, Y; Schoumacher, M; Sellers, WR; Shao, W; Sonkin, D; Steiger, J; Stump, MD; Yan-Neale, Y1
Baxter, RC; Gill, AJ; Hugh, TJ; Julovi, SM; Pavlakis, N; Peters, L; Samra, JS; Smith, RC; Wong, MH; Xue, A1
Baxter, RC; Pavlakis, N; Smith, RC; Wong, MH; Xue, A1
Banno, E; de Velasco, MA; Fujita, Y; Kamata, K; Kitano, M; Kudo, M; Mizukami, T; Nakamura, Y; Nishio, K; Sakai, K; Terashima, M; Togashi, Y1
Irurzun-Arana, I; McDonald, TO; Michor, F; Trocóniz, IF1

Other Studies

5 other study(ies) available for erlotinib hydrochloride and byl719

ArticleYear
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
    Cancer research, 2014, Jun-15, Volume: 74, Issue:12

    Topics: Acetamides; Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidinones; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Tankyrases; Thiazoles; Xenograft Model Antitumor Assays

2014
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Aug-01, Volume: 20, Issue:15

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Neoplasia (New York, N.Y.), 2016, Volume: 18, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Flavonoids; Humans; Imidazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Thiazoles; TOR Serine-Threonine Kinases

2016
Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.
    International journal of oncology, 2017, Volume: 50, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Thiazoles

2017
Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance.
    Cancer research, 2020, 08-15, Volume: 80, Issue:16

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinolines; Software; Thiazoles; Triple Negative Breast Neoplasms

2020